Antisoma Drug to Target Kidney and Skin Cancer
Posted on: Wednesday, 30 August 2006, 12:00 CDT
Cancer drug developer Antisoma has selected renal cancer and melanoma as indications for its new drug, AS1409. The company will now enroll patients with these disorders into a phase I trial.
The company has selected these indications because high levels of the drug's target are found in these cancers.
AS1409 is a fusion protein with two components. It contains IL12 which is known to have anticancer effects. The other component is EDB fibronectin, a protein associated with tumor blood vessels in a wide range of cancers. AS1409 is designed to be a targeted therapy that delivers IL12 specifically to tumors.
Studies have shown that AS1409 is more effective than an equivalent dose of 1L12 and is expected to cause fewer side effects than 1L12 alone.
Antisoma has said that AS1409 has potential against various tumors. Past clinical trials have suggested that melanoma and renal cancer are particularly sensitive to IL12. Samples from 15 melanoma and 20 renal cancer patients were clearly positive, showing these cancers to be suitable for the initial evaluation of the drug.
Source: Datamonitor
Related Articles
- NCCN, Abraxis BioScience and AstraZeneca Announce Collaboration to Conduct Anti-Cancer Drug Studies
- Genentech's Cancer Drug Increases Lung Cancer Survival
- Renal Cancer Drug Pipeline Update Lists All Drugs and Gives You a Progress Analysis on Each One of Them
- Gain An Insight Into The Pipeline Status Of Melanoma Or Skin Cancer Drugs By Company And By Stage As Well As A Summary Of The Latest News And Developments In This Area
- Exelixis Begins Phase II Study for Cancer Drug
- Who's Developing What in New Cancer Drugs 2005?
- Celgene's Cancer Drug Trial Turns Heads
- Onyx's Cancer Drug Gets Boost
- Myriad Genetics Submits IND on MPC-6827 Cancer Drug
- Breast Cancer Drug Cuts Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds